← Who reports today · Health Care
Vertex Pharmaceuticals (VRTX) earnings date & Q3 2026 results
Net income
$654M
down 39.6% y/y
Total revenues
$3,441M
up 11.8% y/y
Income from operations
$713M
down 39.9% y/y
Next report
~ Feb 11
not announced yet
The quarter in brief
Vertex reported GAAP net income of $653.6 million ($2.56 per diluted share) on total revenues of $3,440.8 million for the third quarter of 2026, down from net income of $1,082.9 million ($4.20 per diluted share) on revenues of $3,076.4 million a year earlier.
Key growth driver: Revenue growth of +12% y/y — the report gives no segment split, so the driver is the whole business. · by the Q3 2026 report
- Net income −39.6% — primarily expenses related to the Crinetics Pharmaceuticals acquisition
Source
«GAAP net income was $654 million compared to $1.1 billion for the third quarter of 2025. The year-over-year decline is primarily due to expenses related to the Crinetics Pharmaceuticals acquisition.»
press release, 8-K - Total revenues +11.8% — mainly continued cystic fibrosis therapy sales and diversification into additional disease areas
Source
«Total revenue increased 12% to $3.44 billion compared to the third quarter of 2025, primarily driven by the continued performance of cystic fibrosis (CF) therapies and growth from diversification into additional disease areas.»
press release, 8-K
All figures in $M.
| Line item | Amount and change |
|---|---|
| Total revenues | $3,441 · +11.8% |
| Cost of sales | $526 · +26.8% |
| Research and development expenses | $1,321 · +35.1% |
| Acquired in-process research and development expenses | $40.6 · −25.5% |
| Selling, general and administrative expenses | $844 · +89.6% |
| Change in fair value of contingent consideration | $3.5 · +84.2% |
| Income from operations | $713 · −39.9% · 20.7% margin |
| Interest income | $118 · −5.8% |
| Interest expense | $36 · +991% |
| Other (expense) income, net | $11.9 · +21.4% |
| Income before provision for income taxes | $783 · −39.7% |
| Provision for income taxes | $130 · −39.9% · 16.6% effective rate |
| Net income | $654 · −39.6% · $2.56/sh · 19.0% margin |
Verdict: Vertex reported GAAP net income of $653.6 million ($2.56 per diluted share) on total revenues of $3,440.8 million for the third quarter of 2026, down from net income of $1,082.9 million ($4.20 per diluted share) on revenues of $3,076.4 million a year earlier.
Source and notation
Source: Vertex Pharmaceuticals earnings release, 8-K EX-99 of 11/02/2026 (SEC EDGAR).
Open as an image: Vertex Pharmaceuticals (VRTX), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Vertex Pharmaceuticals (VRTX) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/vrtx. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/vrtx"><img src="https://whoreportstoday.com/t/vrtx/img/vertex-pharmaceuticals-vrtx-earnings-sankey.png" alt="Vertex Pharmaceuticals (VRTX) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/vrtx">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/vrtx/img/vertex-pharmaceuticals-vrtx-earnings-sankey.png
<a href="https://whoreportstoday.com/t/vrtx">Vertex Pharmaceuticals (VRTX) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Total revenues rose 11.9% year over year, from $3,076.4 million to $3,440.8 million.
- Income from operations fell 39.9%, from $1,186.2 million to $712.9 million, lowering the operating margin to 20.7% of revenue from 38.6%.
- Research and development expenses increased 35.1%, from $977.7 million to $1,320.6 million.
- Selling, general and administrative expenses increased 89.6%, from $445.1 million to $844.1 million.
- Interest expense rose to $36.0 million from $3.3 million.
- The GAAP effective tax rate was 16.6% ($129.8 million of tax on $783.4 million of pretax income), versus 16.6% a year earlier ($215.9 million on $1,298.8 million).
- Net income margin was 19.0% of revenue, down from 35.2% a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Reshma KewalramaniChief Executive Officer and President [1]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Vertex Pharmaceuticalssince 2017
- Chief Executive Officer and Presidentsince 2020
- Directorsince 2020
- Executive Vice President and Chief Medical Officer2018–2020
- Senior Vice President, Late Development2017–2018
- Ginkgo Bioworks2021–2024Director
- Amgen2004–2017Vice President and Head of U.S. Medical Organization
Source: SEC EDGAR: DEF 14A proxy statement, 2026-04-02 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 1
- SEC EDGAR: 10-Q 2026-11-03 · SEC EDGAR · 11/18/2026
Vertex Pharmaceuticals — Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative treatments for serious diseases, particularly cystic fibrosis.
It is headquartered in Boston, Massachusetts.
Heads-up
- net income fell 40% y/y in Q3 2026
Net income for Q3 2026: $654M, −40% y/y. In the report's figures: costs grew faster than revenue: selling, general and administrative expenses +90% y/y, research and development expenses +35% y/y, interest expense +991% y/y. The company explains: primarily expenses related to the Crinetics Pharmaceuticals acquisition (press release, 8-K). Based on the Q3 2026 report.
The company's report ↗Company reports
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2026 | revenue $13.15–13.25B | revenue $12BEPS (GAAP) $15.32 | revenue +10% |
Same quarter a year ago (ended December 31, 2025): revenue $3.19B, EPS (GAAP) $4.64
How we calculate
Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +10%).
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Nov 2, 2026); every figure is checked against the release text.
VRTX earnings history: past report dates
| Aug 3, 2026 Mon | 4:09 pmafter market close | Jun 30, 2026 | $3.3B+12% y/y | $4.31+8% y/y |
| May 4, 2026 Mon | 4:05 pmafter market close | Mar 31, 2026 | $3.0B+8% y/y | $4.02+61% y/y |
| Feb 12, 2026 Thu | 4:04 pmafter market close | Dec 31, 2025 | ≈$3.2B+10% y/y | ≈$4.64+28% y/y |
| Nov 3, 2025 Mon | 4:06 pmafter market close | Sep 30, 2025 | $3.1B+11% y/y | $4.20+5% y/y |
| Aug 4, 2025 Mon | 4:06 pmafter market close | Jun 30, 2025 | $3.0B+12% y/y | $3.99 |
| May 5, 2025 Mon | 4:10 pmafter market close | Mar 31, 2025 | $2.8B+3% y/y | $2.49−41% y/y |
| Feb 10, 2025 Mon | 4:08 pmafter market close | Dec 31, 2024 | ≈$2.9B+16% y/y | ≈$3.62−2% y/y |
| Nov 4, 2024 Mon | 4:02 pmafter market close | Sep 30, 2024 | $2.8B+12% y/y | $4.01+1% y/y |
| Aug 1, 2024 Thu | 4:05 pmafter market close | Jun 30, 2024 | $2.6B+6% y/y | −$13.92 |
| May 6, 2024 Mon | 4:03 pmafter market close | Mar 31, 2024 | $2.7B+13% y/y | $4.21+57% y/y |
| Feb 5, 2024 Mon | 4:09 pmafter market close | Dec 31, 2023 | ≈$2.5B+9% y/y | ≈$3.71+18% y/y |
| Nov 6, 2023 Mon | 4:05 pmafter market close | Sep 30, 2023 | $2.5B+6% y/y | $3.97+11% y/y |
| Aug 1, 2023 Tue | 4:03 pmafter market close | Jun 30, 2023 | $2.5B+14% y/y | $3.52+12% y/y |
| May 1, 2023 Mon | 4:08 pmafter market close | Mar 31, 2023 | $2.4B+13% y/y | $2.69−9% y/y |
| Feb 7, 2023 Tue | 4:07 pmafter market close | Dec 31, 2022 | ≈$2.3B+11% y/y | ≈$3.14+5% y/y |
| Oct 27, 2022 Thu | 4:06 pmafter market close | Sep 30, 2022 | $2.3B+18% y/y | $3.59+9% y/y |
Show all 16 reports since 2022Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Vertex Pharmaceuticals: 15-year financials
| 2025 | 12,001 | 4,173 | 3,953 | 3,194 |
| 2024 | 11,020 | −233 | −536 | −790 |
| 2023 | 9,869 | 3,832 | 3,620 | 3,337 |
| 2022 | 8,931 | 4,307 | 3,322 | 3,925 |
| 2021 | 7,574 | 2,782 | 2,342 | 2,409 |
| 2020 | 6,206 | 2,856 | 2,712 | 2,994 |
| 2019 | 4,163 | 1,198 | 1,177 | 1,494 |
| 2018 | 3,048 | 635 | 2,097 | 1,175 |
| 2017 | 2,489 | 123 | 264 | 746 |
| 2016 | 1,702 | 9.9 | −112 | 180 |
| 2015 | 1,032 | −467 | −556 | −411 |
| 2014 | 580 | −692 | −739 | −624 |
| 2013 | 1,212 | −610 | −445 | −112 |
| 2012 | 1,527 | 46.7 | −107 | 197 |
| 2011 | 1,411 | 114 | 29.6 | 109 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Vertex Pharmaceuticals: 15-year balance sheet
| Year | Assets | Equity | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|
| 2025 | 25,643 | 18,666 | 5,085 | 11,201 | 3,861 |
| 2024 | 22,533 | 16,410 | 4,570 | 9,596 | 3,565 |
| 2023 | 22,730 | 17,580 | 10,369 | 14,144 | 3,547 |
| 2022 | 18,151 | 13,913 | 10,504 | 13,235 | 2,742 |
| 2021 | 13,433 | 10,100 | 6,795 | 9,561 | 2,142 |
| 2020 | 11,752 | 8,687 | 5,988 | 8,133 | 1,878 |
| 2019 | 8,319 | 6,085 | 3,109 | 4,823 | 1,335 |
| 2018 | 6,246 | 4,435 | 2,650 | 3,843 | 1,120 |
| 2017 | 3,546 | 2,029 | 1,665 | 2,649 | 807 |
| 2016 | 2,897 | 1,157 | 1,184 | 1,832 | 793 |
| 2015 | 2,499 | 940 | 715 | 1,407 | 506 |
| 2014 | 2,335 | 1,075 | 625 | 1,547 | 368 |
| 2013 | 2,319 | 1,356 | 569 | 1,589 | 398 |
| 2012 | 2,759 | 999 | 489 | 1,590 | 433 |
| 2011 | 2,204 | 787 | 475 | 1,331 | 392 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 3,197 | 3,133 | +63.2 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 182 | 154 | |
| · incl. stock-based comp (non-cash)share-based compensation | 511 | 528 | |
| Capexpurchases of property & equipment | −343 | −288 | −54.7 |
| Free cash flow ≈operating cash flow − capex | 2,854 | 2,845 | +8.5 |
| Investing activities, netcapex, acquisitions, securities | −6,578 | −657 | −5,921 |
| · incl. acquisitionsbusinesses net of cash acquired | −9,063 | 0 | −9,063 |
| Financing activities, netdebt, buybacks, dividends | 3,331 | −2,184 | +5,516 |
| · incl. buybacksrepurchases of common stock | −933 | −1,889 | +956 |
| FX effect on cash | −48.9 | 83.6 | −133 |
| Net change in cash | −99.2 | 376 | −475 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 30, 2026: $20.9B (64% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Feb 202610-K FY2025: apart from Note P, the company is not party to any material legal proceedings; no shareholder suits and no SEC cases. sec.gov ↗
- Feb 2026Shares outstanding of 254.0M vs. 260.0M in January 2021 (−2.3%); SBC 5.7% of revenue. data.sec.gov ↗
1 more fact and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Apr 20262026 proxy: the only related-party transaction in 2025 was the COO/CFO's daughter, ~$155K. sec.gov ↗
Scoring: 2.0, no deductions: single share class, share count −2.3% over 5 years, SBC 5.7% of revenue (<10%), no dividends and no policy, no shareholder suits or SEC cases = 2.0
- Share classes
- Single class of common stock (Nasdaq: VRTX).
- Dilution
- Shares 260.0M (January 2021) → 254.0M (February 2026), −2.3%; SBC $686M = 5.7% of revenue (<10%); buybacks of $0.4–2.0B a year.
- Disclosure
- Full 10-K/10-Q reporting.
- Dividends
- No dividends and no payout policy.
- Lawsuits & regulators
- 10-K: no material legal proceedings (other than those described in Note P); no shareholder suits and no SEC cases.
- Related parties
- 2026 proxy: the only transaction is the COO/CFO's daughter in a non-executive role, ~$155K.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies with revenue growth 10 years in a row
Vertex Pharmaceuticals (VRTX) earnings: FAQ
When is VRTX's next earnings date?
We have not yet seen an announcement of the date from Vertex Pharmaceuticals (VRTX). Based on last year's report on Feb 12, 2026, the next report is expected around Feb 11, 2027.
What time does VRTX report earnings?
Vertex Pharmaceuticals usually reports after market close: its latest results release was filed with the SEC at 4:09 pm ET on Aug 3, 2026.
When did VRTX last report earnings?
Vertex Pharmaceuticals reported Q3 2026 results on Nov 2, 2026.
What has Vertex Pharmaceuticals guided for FY2026?
Company guidance for FY2026: revenue $13.15–13.25B. A year ago (FY2025): revenue $12B, EPS (GAAP) $15.32. Implied growth: revenue +10%. Source: the company's earnings release (Form 8-K filed Nov 2, 2026).
Where can I find Vertex Pharmaceuticals's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to VRTX's filings; this page breaks the latest report down in a Sankey chart.
What was VRTX's net income in Q3 2026?
Vertex Pharmaceuticals reported net income of $654M for Q3 2026 (−39.6% year over year), under US GAAP.
How has Vertex Pharmaceuticals's revenue changed since 2011?
Per its 10-K filings, revenue grew 8.5x: $1,411M in 2011 and $12,001M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: VTRS · Q2 2026 · WAT · Q3 2026 · WST · Q3 2026 · ZBH · Q3 2026 · ZTS · Q3 2026 · A · Q3 FY2026 · ABBV · Q3 2026 · ABT · Q3 2026 · ALGN · Q3 2026 · AMGN · Q3 2026 · all reports